Back to Search
Start Over
Liraglutide prevents metabolic side-effects and improves recognition and working memory during antipsychotic treatment in rats.
- Source :
-
Journal of Psychopharmacology . May2018, Vol. 32 Issue 5, p578-590. 13p. - Publication Year :
- 2018
-
Abstract
- <bold>Background: </bold>Antipsychotic drugs (APDs), olanzapine and clozapine, do not effectively address the cognitive symptoms of schizophrenia and can cause serious metabolic side-effects. Liraglutide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist with anti-obesity and neuroprotective properties. The aim of this study was to examine whether liraglutide prevents weight gain/hyperglycaemia side-effects and cognitive deficits when co-administered from the commencement of olanzapine and clozapine treatment.<bold>Methods: </bold>Rats were administered olanzapine (2 mg/kg, three times daily (t.i.d.)), clozapine (12 mg/kg, t.i.d.), liraglutide (0.2 mg/kg, twice daily (b.i.d.)), olanzapine + liraglutide co-treatment, clozapine + liraglutide co-treatment or vehicle (Control) ( n = 12/group, 6 weeks). Recognition and working memory were examined using Novel Object Recognition (NOR) and T-Maze tests. Body weight, food intake, adiposity, locomotor activity and glucose tolerance were examined.<bold>Results: </bold>Liraglutide co-treatment prevented olanzapine- and clozapine-induced reductions in the NOR test discrimination ratio ( p < 0.001). Olanzapine, but not clozapine, reduced correct entries in the T-Maze test ( p < 0.05 versus Control) while liraglutide prevented this deficit. Liraglutide reduced olanzapine-induced weight gain and adiposity. Olanzapine significantly decreased voluntary locomotor activity and liraglutide co-treatment partially reversed this effect. Liraglutide improved clozapine-induced glucose intolerance.<bold>Conclusion: </bold>Liraglutide co-treatment improved aspects of cognition, prevented obesity side-effects of olanzapine, and the hyperglycaemia caused by clozapine, when administered from the start of APD treatment. The results demonstrate a potential treatment for individuals at a high risk of experiencing adverse effects of APDs. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 02698811
- Volume :
- 32
- Issue :
- 5
- Database :
- Academic Search Index
- Journal :
- Journal of Psychopharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 129450563
- Full Text :
- https://doi.org/10.1177/0269881118756061